Compugen Ltd. (NASDAQ: CGEN) stock fell -0.15% on Monday to $0.86 against a previous-day closing price of $0.87. With 0.95 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.7 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.8704 whereas the lowest price it dropped to was $0.8300. The 52-week range on CGEN shows that it touched its highest point at $3.94 and its lowest point at $0.51 during that stretch. It currently has a 1-year price target of $6.14. Beta for the stock currently stands at 2.57.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CGEN was down-trending over the past week, with a drop of -18.52%, but this was up by 3.44% over a month. Three-month performance dropped to -1.01% while six-month performance fell -53.31%. The stock lost -77.33% in the past year, while it has gained 20.68% so far this year. A look at the trailing 12-month EPS for CGEN yields -0.46 with Next year EPS estimates of -0.53. For the next quarter, that number is -0.14. This implies an EPS growth rate of -8.90% for this year and -8.20% for next year.
Float and Shares Shorts:
At present, 86.62 million CGEN shares are outstanding with a float of 81.78 million shares on hand for trading. On Oct 13, 2022, short shares totaled 2.83 million, which was 3.26% higher than short shares on Sep 14, 2022. In addition to Dr. Anat Cohen-Dayag Ph.D. as the firm’s CEO, Pres & Director, Mr. Ari Krashin serves as its Chief Financial & Operating Officer.
Through their ownership of 26.29% of CGEN’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 16.00% of CGEN, in contrast to 10.08% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in CGEN with 2.74% of the stake, Renaissance Technologies LLC holds 2,372,648 shares worth 2,372,648. A second-largest stockholder of CGEN, The Vanguard Group, Inc., holds 1,908,162 shares, controlling over 2.20% of the firm’s shares. Davidson Kempner Capital Manageme is the third largest shareholder in CGEN, holding 1,900,000 shares or 2.19% stake. With a 6.34% stake in CGEN, the Nikko AM Global Umbrella Fund – A is the largest stakeholder. A total of 5,495,822 shares are owned by the mutual fund manager. The ARK Israel Innovative Technology, which owns about 2.76% of CGEN stock, is the second-largest Mutual Fund holder. It holds 2,389,242 shares valued at 1.71 million. Vanguard Total International Stoc holds 1.16% of the stake in CGEN, owning 1,000,271 shares worth 0.72 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CGEN since 7 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CGEN analysts setting a high price target of $13.00 and a low target of $1.00, the average target price over the next 12 months is $6.14. Based on these targets, CGEN could surge 1411.63% to reach the target high and rise by 16.28% to reach the target low. Reaching the average price target will result in a growth of 613.95% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CGEN will report FY 2022 earnings on 02/22/2024. Analysts have provided yearly estimates in a range of -$0.41 being high and -$0.51 being low. For CGEN, this leads to a yearly average estimate of -$0.47. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Compugen Ltd. surprised analysts by -$0.02 when it reported -$0.14 EPS against a consensus estimate of -$0.12. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.12 and the low estimate is -$0.16. The average estimate for the next quarter is thus -$0.14.